LOY-001: IGF-1-lowering long-acting injection for large and giant breed dogs (Loyal)

LOY-001 is Loyal's long-acting injectable intended to extend healthy lifespan in large and giant breed dogs aged 7 years or older weighing at least 40 lb by lowering IGF-1, given every three to six months. The FDA accepted its reasonable-expectation-of-effectiveness technical section in 2023. No trial design or results have been published.

Record

Designcompany regulatory program
Statusongoing
InterventionLOY-001, a prescription long-acting injection that reduces IGF-1 levels
Intervention classdrug
Dose regimeninjection administered by a veterinarian every three to six months
Breedlarge and giant breeds
Age7 years and older, weighing at least 40 lb
Primary outcomehealthy lifespan extension
Lead organisationLoyal (San Francisco)
Sponsor or funderLoyal
Tagslifespan, drug, igf-1, large-breeds, fda-conditional-approval, loyal

Notes: Company- and press-sourced only; trial size, design and results undisclosed as of 2026-10-01.

Sources and verbatim quotes

Loyal: for dog owners (company page) (2026), snapshot loyal-for-dog-owners (company)

Loyal drug LOY-001 to extend lifespan of giant dog breeds (Gizmodo) (2023), snapshot gizmodo-loy-001 (press)

Reproduce: canine_trial_search(trial_id="loyal-loy-001-large-dogs") in dog-geroscience-mcp; dataset canine-trial-registry.